Eli Lilly and Co/ US5324571083 /
14/11/2024 19:51:38 | Diferencia -15.30 | Volumen | Bid19:51:38 | Ask19:51:38 | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
796.51USD | -1.88% | 2.14 millones Volumen de negocios: 998.56 millones |
796.21Volumen de oferta: 700 | 796.69Tamaño/ Volumen/ Formato de Ask: 100 | 754.82 mil millonesUSD | 0.59% | 136.62 |
Newsfile Corp
16/09
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Newsfile Corp
28/08
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
27/08
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
21/08
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
21/08
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
14/08
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
14/08
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
07/08
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
06/08
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
06/08
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
02/08
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
01/08
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
01/08
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página